Patent application number | Description | Published |
20080214821 | Method of Preparing Clopidogrel and Intermediates Used Therein - Optically pure clopidogrel can be prepared in a high yield by optically resolving a racemic form of the compound of formula (II) using an optically active amine to form the optically active form of the compound of formula (III) or its acid-addition salt; and methylating the compound of formula (III) or its acid-addition salt. | 09-04-2008 |
20090036683 | METHOD FOR PREPARING CLOPIDOGREL 1,5-NAPHTHALENEDISULFONATE OR HYDRATE THEREOF - The present invention relates to a method for preparing clopidogrel 1,5-naphthalenedisulfonate or a hydrate thereof, which comprises reacting a clopidogrel-acid addition salt with disodium 1,5-naphthalenedisulfonate or its hydrate in water, or a mixture of water and an organic solvent. High quality clopidogrel 1,5-naphthalenedisulfonate can be prepared by the inventive method by way of using non-corrosive disodium 1,5-naphthalenedisulfonate. | 02-05-2009 |
20090318375 | Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same - This invention provides a crystalline azithromycin L-malate monohydrate for treating various microbial infections, which has high thermostability, solubility and non-hygroscopicity, a method for preparing same, and a pharmaceutical composition containing same. | 12-24-2009 |
20090318701 | METHOD PREPARATION CLOPIDOGREL AND INTERMEDIATES USED THEREIN - Optically pure clopidogrel can be prepared in a high yield by optically resolving a racemic form of the compound of formula (II) using an optically active amine to form the optically active form of the compound of formula (III) or its acid-addition salt; and methylating the compound of formula (III) or its acid-addition salt. | 12-24-2009 |
20100120888 | ATORVASTATIN STRONTIUM SALT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - This invention provides atorvastatin strontium salt or its hydrates or polymorphs having improved water solubility, which is useful for the prevention or treatment of hyperlipidemia and hypercholesterolemia, and a pharmaceutical composition comprising same. | 05-13-2010 |
20120130629 | METHOD FOR AVOIDING SIDE COLLISION OF VEHICLES - A method for avoiding side collision of vehicles at cross roads (where two or more roads meet) by utilizing a side collision prediction algorithm. The method for avoiding side collision of vehicles includes the steps of controlling the movement of the vehicle that is compliant with the traffic light and has started moving, by either rapid acceleration or deceleration when the driver of a first vehicle is unable to promptly respond to a second vehicle approaching from the side (left to right or right to left) in violation of the traffic light signal, or in cases where a collision is unavoidable, by causing the collision to occur as far away from the occupant compartment of the first vehicle as possible to minimize any injuries of the passengers in the first vehicle. | 05-24-2012 |
20140357517 | RADIATION EXPOSURE DIAGNOSTIC MARKER IGFBP-5, COMPOSITION FOR RADIATION EXPOSURE DIAGNOSIS BY MEASURING THE EXPRESSION LEVEL OF THE MARKER, RADIATION EXPOSURE DIAGNOSTIC KIT COMPRISING THE COMPOSITION, AND METHOD FOR DIAGNOSING RADIATION EXPOSURE USING THE MARKER - The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection. | 12-04-2014 |
20150141486 | COMPOSITION COMPRISING miRNA FOR ENHANCING RADIATION SENSITIVITY - Provided are a method of enhancing radiation sensitivity by using miR-499b-5p and a method of treating a radiation resistant cancer including administering miR-499b-5p. | 05-21-2015 |